O'Hurley Gillian, Sjöstedt Evelina, Rahman Arman, Li Bo, Kampf Caroline, Pontén Fredrik, Gallagher William M, Lindskog Cecilia
UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85 Uppsala, Sweden; OncoMark Ltd, NovaUCD, Belfield Innovation Park, Belfield, Dublin 4, Ireland.
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85 Uppsala, Sweden.
Mol Oncol. 2014 Jun;8(4):783-98. doi: 10.1016/j.molonc.2014.03.008. Epub 2014 Mar 21.
The use of immunohistochemistry (IHC) in clinical cohorts is of paramount importance in determining the utility of a biomarker in clinical practice. A major bottleneck in translating a biomarker from bench-to-bedside is the lack of well characterized, specific antibodies suitable for IHC. Despite the widespread use of IHC as a biomarker validation tool, no universally accepted standardization guidelines have been developed to determine the applicability of particular antibodies for IHC prior to its use. In this review, we discuss the technical challenges faced by the use of immunohistochemical biomarkers and rigorously explore classical and emerging antibody validation technologies. Based on our review of these technologies, we provide strict criteria for the pragmatic validation of antibodies for use in immunohistochemical assays.
免疫组织化学(IHC)在临床队列中的应用对于确定生物标志物在临床实践中的效用至关重要。将生物标志物从实验室转化到临床应用的一个主要瓶颈是缺乏适用于免疫组织化学的特征明确、特异性强的抗体。尽管免疫组织化学作为生物标志物验证工具被广泛使用,但在使用前尚未制定普遍接受的标准化指南来确定特定抗体用于免疫组织化学的适用性。在本综述中,我们讨论了使用免疫组织化学生物标志物所面临的技术挑战,并严格探索经典和新兴的抗体验证技术。基于对这些技术的综述,我们为免疫组织化学分析中抗体的实际验证提供了严格的标准。